MGNX News and Press, MacroGenics Inc. From 10/25/19

SHANGHAI, China and SAN FRANCISCO, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that its partner MacroGenics, Inc. (NASDAQ: MGNX) has dosed the first patient in the Phase 2/3 M...

The first patient has been dosed in MacroGenics' (NASDAQ: MGNX ) Phase 2/3 MAHOGANY clinical trial of margetuximab, a Fc-optimized monoclonal antibody targeting HER2, in combination with a checkpoint inhibitor, with or without chemotherapy, as a potential first-line treatment for patients ...

Rockville, MD, Oct. 25, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the first patient has be...

Shares of MacroGenics (NASDAQ: MGNX) , a small-cap clinical-stage biopharma focused on cancer , dropped 15% as of 3:13 p.m. EDT on Wednesday. The double-digit swoon is traceable to a clinical update that was shared with investors. MacroGenics announced top-line results from its second pre-s...

Gainers:  Tile Shop Holdings (NASDAQ: TTS ) +53% . Cemtrex (NASDAQ: CETX ) +40% . PB Bancorp (NASDAQ: PBBI ) +30% . Sunworks (NASDAQ: SUNW ) +24% . The Dixie Group (NASDAQ: DXYN ) +24% . Nautilus (NYSE: NLS ) +22% . Nano Dimension (NASDAQ: NNDM ) +22% . Trans World Entertainmen...

Gainers:  MANH   +5.6% . MRNA   +4.2% . USNA   +3.3% . FTDR   +2.1%.  ZUMZ   +1.9% . More news on: Manhattan Associates, Inc., Moderna, Inc., USANA Health Sciences, Inc., Stocks on the move, , News on ETFs Read more ...

A second pre-planned interim overall survival (OS) analysis of a Phase 3 clinical trial, SOPHIA , evaluating MacroGenics' (NASDAQ: MGNX ) margetuximab, an HER2-targeting monoclonal antibody, plus chemo compared to Roche's Herceptin (trastuzumab) plus chemo in patients with HER2-positive met...

ROCKVILLE, MD, Oct. 22, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced topline results from the second ...

NEW YORK, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP  announces that a federal securities class action lawsuit has been filed in the United States District Court for the District of Maryland on behalf of all investors that purchased MacroGenics, ...

ROCKVILLE, MD, Sept. 30, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced updated results from a Phase 2 ...